Search results for "OPINION"

showing 10 items of 389 documents

MycoKey Round Table Discussions of Future Directions in Research on Chemical Detection Methods, Genetics and Biodiversity of Mycotoxins

2018

MycoKey, an EU-funded Horizon 2020 project, includes a series of “Roundtable Discussions” to gather information on trending research areas in the field of mycotoxicology. This paper includes summaries of the Roundtable Discussions on Chemical Detection and Monitoring of mycotoxins and on the role of genetics and biodiversity in mycotoxin production. Discussions were managed by using the nominal group discussion technique, which generates numerous ideas and provides a ranking for those identified as the most important. Four questions were posed for each research area, as well as two questions that were common to both discussions. Test kits, usually antibody based, were one major focus of the…

0301 basic medicineProteomicsSettore CHIM/01 - CHIMICA ANALITICAComputer scienceHealth Toxicology and MutagenesisBiodiversitylcsh:Medicinebiological controlmicrobiomeToxicology//purl.org/becyt/ford/1 [https]transcriptomicscommunication with non-scientistsA better understanding of metabolomics from the cellular to the ecosystem level is needed to inform and control mycotoxin production control and remediation. Antibody-based diagnostics have become an acceptable standard in many practical applications but sophisticated multi-mycotoxin detection protocols are the future for many official regulatory controls especially as the number of toxins that are regulated increases and need more standardization and cross-laboratory validation.antibodies2. Zero hungerGeneticsbiologyNominal groupBiodiversitymetabolomicsGeneral partnershipBiological controlAntibodiesBiological controlCommunication with non-scientists Metabolomics Microbiome Multi-mycotoxin detection protocols Nominal group discussion technique ProteomicsTranscriptomicsmulti-mycotoxin detection protocolsSettore AGR/12 - PATOLOGIA VEGETALECommunication with non-scientistsEnvironmental MonitoringNominal group discussion techniqueOpinionAntibodies03 medical and health sciencesMycotoxicologyBiointeractions and Plant HealthproteomicsFood supplyAnimalsHumansMetabolomicsnominal group discussion technique//purl.org/becyt/ford/1.6 [https]Transcriptomicsbusiness.industryResearchlcsh:RUsabilityMycotoxinsbiology.organism_classification030104 developmental biologyMulti-mycotoxin detection protocolsRound tableRankingMicrobiomeEPSbusinesscommunication with non-scientistToxins
researchProduct

Innate and Adaptive Immunity in Aging and Longevity: The Foundation of Resilience

2020

The interrelation of the processes of immunity and senescence now receives an unprecedented emphasis during the COVID-19 pandemic, which brings to the fore the critical need to combat immunosenescence and improve the immune function and resilience of older persons. Here we review the historical origins and the current state of the science of innate and adaptive immunity in aging and longevity. From the modern point of view, innate and adaptive immunity are not only affected by aging but also are important parts of its underlying mechanisms. Excessive levels or activity of antimicrobial peptides, C-reactive protein, complement system, TLR/NF-κB, cGAS/STING/IFN 1,3 and AGEs/RAGE pathways, mye…

0301 basic medicineSenescencemedia_common.quotation_subjectBiologyPathology and Forensic Medicine03 medical and health sciences0302 clinical medicineImmune systemBiomarkers of aginglongevityImmunityinnate immunityresiliencemedia_commonSettore MED/04 - Patologia GeneraleInnate immune systemagingLongevityCell BiologyImmunosenescenceadaptive immunityOpinion ArticleAcquired immune system030104 developmental biologyImmunologyNeurology (clinical)Geriatrics and Gerontology030217 neurology & neurosurgeryAging and Disease
researchProduct

Assessment of genetically modified maize 1507 × NK603 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐008)

2018

International audience; Following the submission of application EFSA-GMO-RX-008 under Regulation (EC) No 1829/2003 from Pioneer Hi-Bred International, Inc. and Dow AgroSciences LLC, the Panel on Genetically Modified Organisms of the European Food Safety Authority was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application for the insect-resistant, herbicide-tolerant genetically modified maize 1507 x NK603, for food and feed uses, import and processing, excluding cultivation within the EU. The data received in the context of this renewal application contained a systematic search and evaluation of literature, updated bioin…

0301 basic medicineVeterinary (miscellaneous)[SDV]Life Sciences [q-bio]Plant Science010501 environmental sciences01 natural sciencesMicrobiology[SHS]Humanities and Social Sciences03 medical and health sciences1507 × NK603[SDV.IDA]Life Sciences [q-bio]/Food engineering[SDV.BV]Life Sciences [q-bio]/Vegetal Biology[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineering0105 earth and related environmental sciences2. Zero hungerrenewalGmoRegulation (EC) No 1829/2003Maize030104 developmental biologyScientific Opinion[SDE]Environmental Sciences1507 x NK603ParasitologyAnimal Science and ZoologyArticles 11 and 23Food ScienceRegulation (EC) No 1829/2003
researchProduct

Statement of the Prolamin Working Group on the Determination of Gluten in Fermented Foods Containing Partially Hydrolyzed Gluten

2021

On August 12, 2020, the U.S. Food and Drug Administration (FDA) has finalized a rule related to gluten-free labeling for foods containing fermented, hydrolyzed ingredients. The FDA believes that there is no scientifically valid analytical method effective for determining gluten in fermented or hydrolyzed foods. In the absence of an analytical method, the FDA has decided to evaluate gluten-free claims on these foods based only on evidence that the food or ingredient used is gluten-free before fermentation or hydrolysis. For example, barley-based beers from which gluten is removed during brewing using special filtration, adsorption and/or enzymatic treatment are therefore excluded from bearin…

0301 basic medicineanalysifermented foodanalysisEndocrinology Diabetes and MetabolismIngredientProlaminFood scienceIngredient0302 clinical medicinehydrolysed beer[SDV.IDA]Life Sciences [q-bio]/Food engineeringFood scienceFermentation in food processingComputingMilieux_MISCELLANEOUS2. Zero hungerchemistry.chemical_classificationNutrition and DieteticsbiologyChemistryHydrolysisdigestive oral and skin physiologyfood and beveragesQuímicaChemistryFermentation in food processingProlamin Working Groupgluten-free foodpartially hydrolyzed glutenlcsh:Nutrition. Foods and food supplyLife sciences; biologyOpinioncompetitive ELISAlcsh:TX341-641030209 endocrinology & metabolismdigestive systemFood and drug administration03 medical and health sciencesHydrolysisddc:570ProlaminLC-MS/MSFood and drug administrationNutrition030109 nutrition & dieteticsbusiness.industrynutritional and metabolic diseasesBrewingGlutendigestive system diseasesPlant BreedingglutenFermentationbiology.proteinBrewingFermentation[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiebusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutritionceliac diseaseFrontiers in Nutrition
researchProduct

Bordeaux 2018: Wine, Cheese, and γδ T Cells

2019

The first ‘International γδ T cell conference’ took place in Denver, CO (USA) in 2004. Since then, a new meeting is held every two years. During each conference, all participants voted to choose between candidate bids for where to hold the next conference. At the conference held in London in 2016, a majority opted for the bid from a team proposing the 2018 event be held in Bordeaux, France – which is where we therefore gathered on 7-10th of June 2018. The meeting was an undisputed success and it gave us the opportunity to take stock of the increasing basic knowledge about γδ T cells as well as the rapidly expanding interest and activities developing using γδ T cells towards clinical applica…

0301 basic medicinelcsh:Immunologic diseases. AllergyOpinionrecent advancesT cellImmunologyReceptors Lymphocyte HomingLibrary scienceInfectionsLymphocyte Activation03 medical and health sciences0302 clinical medicineBasic knowledgeongoing researchT-Lymphocyte SubsetsPolitical scienceNeoplasmsmedicineImmunology and AllergyAnimalsHumansgamma delta T cellsInflammationButyrophilinsReceptors Antigen T-Cell gamma-deltaCongresses as Topicfutures perspectives030104 developmental biologymedicine.anatomical_structureconference reportImmunotherapylcsh:RC581-607030215 immunologyFrontiers in Immunology
researchProduct

Assessment of genetically modified maize NK603 x MON810 for renewal of authorisation under Regulation (EC) No 1829/2003 (application EFSA‐GMO‐RX‐007)

2018

Efsa Panel On Genetically Modified Organisms (gmo)Scientific opinionRequestor:European Commission (DG SANTE)Question number:EFSA-Q-2017-00028; Following the submission of application EFSA-GMO-RX-007 under Regulation (EC) No 1829/2003 from Monsanto, the Panel on Genetically Modified Organisms of the European Food Safety Authority (GMO Panel) was asked to deliver a scientific risk assessment on the data submitted in the context of the renewal of authorisation application of the herbicide-tolerant and insect-resistant genetically modified maize NK603 x MON810. The data received in the context of this renewal application contained post-market environmental monitoring reports, a systematic searc…

0301 basic medicinemaïsVeterinary (miscellaneous)gmo[SDV]Life Sciences [q-bio]2405 ParasitologyogmTP1-1185Plant SciencemaizeMicrobiologyzea mays03 medical and health sciences0404 agricultural biotechnology1110 Plant Sciencearticles 11 and 23TX341-6411106 Food ScienceNK603xMON8102. Zero hungerrenewal030109 nutrition & dieteticsNutrition. Foods and food supplymaize; NK603xMON810; renewal; articles 11 and 23; Regulation (EC) No1829/2003indian cornChemical technology2404 MicrobiologyRegulation (EC) No 1829/2003maize;NK603 x MON810;renewal;articles 11 and 23;Regulation (EC) No 1829/2003NK603 x MON81010079 Institute of Veterinary Pharmacology and Toxicology04 agricultural and veterinary sciences040401 food scienceSettore AGR/02 - Agronomia E Coltivazioni Erbacee3401 Veterinary (miscellaneous)Scientific OpinionSettore AGR/11 - Entomologia Generale E ApplicataRegulation (EC) No1829/2003570 Life sciences; biologyAnimal Science and ZoologyParasitology1103 Animal Science and ZoologyNK603 x MON810Regulation (EC) No 1829/2003Food Science
researchProduct

Is erythropoietin a worthy candidate for traumatic brain injury or are we heading the wrong way?

2016

Traumatic brain injury (TBI) is a leading cause of death and disability in the modern society. Although primary prevention is the only strategy that can counteract the primary brain damage, numerous preclinical studies have been accumulated in order to find therapeutic strategies against the secondary damage. In this scenario erythropoietin (EPO) has been shown to be a promising candidate as neuroprotective agent. A recent clinical trial, however, has shown that EPO has not an overall effect on outcomes following TBI thus renewing old concerns.  However, the results of a prespecified sensitivity analysis indicate that the effect of EPO on mortality remains still unclear. In the light of the…

0301 basic medicinemedicine.medical_specialtyMolecular PharmacologyNeuropharmacology & PsychopharmacologyTraumatic brain injurySolid baseBrain damageNeuroprotectionGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesTraumatic brain injury0302 clinical medicinePrimary preventionmedicineGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicineErythropoietin; Neuroprotection; Traumatic brain injuryErythropoietinCause of deathGeneral Immunology and Microbiologybusiness.industryArticlesGeneral MedicineOpinion Articlemedicine.diseaseNeuroprotectionClinical trial030104 developmental biologyErythropoietinmedicine.symptombusinessNeuroscience030217 neurology & neurosurgerymedicine.drugF1000Research
researchProduct

Secondary findings from whole-exome/genome sequencing evaluating stakeholder perspectives. A review of the literature

2019

IF 2.004 (2017); International audience; With the development of next generation sequencing, beyond identifying the cause of manifestations that justified prescription of the test, other information with potential interest for patients and their families, defined as secondary findings (SF), can be provided once patients have given informed consent, in particular when therapeutic and preventive options are available. The disclosure of such findings has caused much debate. The aim of this work was to summarize all opinion-based studies focusing on SF, so as to shed light on the concerns that this question generate. A review of the literature was performed, focusing on all PubMed articles repo…

0301 basic medicinemedicine.medical_specialtyPatientsGenetic CounselingDisclosure[SDV.GEN.GH] Life Sciences [q-bio]/Genetics/Human genetics030105 genetics & heredityChoice Behavior03 medical and health sciencesSecondary findingsStakeholder ParticipationInformed consentMultidisciplinary approachExome SequencingGeneticsmedicineHumansGenetic TestingMedical prescriptionExomeGenetics (clinical)Literature reviewIncidental FindingsOpinion based studiesModalitiesStakeholderSubject (documents)General Medicine3. Good healthTest (assessment)030104 developmental biologyAttitude[SDV.GEN.GH]Life Sciences [q-bio]/Genetics/Human geneticsFamily medicinePsychologyActionabilityEuropean Journal of Medical Genetics
researchProduct

Expert Opinion on Three Phage Therapy Related Topics: Bacterial Phage Resistance, Phage Training and Prophages in Bacterial Production Strains

2018

Phage therapy is increasingly put forward as a "new" potential tool in the fight against antibiotic resistant infections. During the "Centennial Celebration of Bacteriophage Research" conference in Tbilisi, Georgia on 26-29 June 2017, an international group of phage researchers committed to elaborate an expert opinion on three contentious phage therapy related issues that are hampering clinical progress in the field of phage therapy. This paper explores and discusses bacterial phage resistance, phage training and the presence of prophages in bacterial production strains while reviewing relevant research findings and experiences. Our purpose is to inform phage therapy stakeholders such as po…

0301 basic medicinephage therapyPhage therapyprophagemedicine.medical_treatmentviruses030106 microbiologylcsh:QR1-502Resistance (psychoanalysis)adaptationlcsh:MicrobiologyBacteriophageresistance03 medical and health sciencesAntibiotic resistanceVirologyPolitical sciencemedicineBacteriophageProphageComputingMilieux_MISCELLANEOUSbiologybusiness.industryConference ReportregulationPublic relationsResearch findingsbiology.organism_classification[SDV.MP.BAC]Life Sciences [q-bio]/Microbiology and Parasitology/Bacteriology3. Good healthInfectious DiseasesExpert opinionproductionbusinessViruses
researchProduct

Exploring the association between extra-cardiac troponin elevations and risk of future mortality

2019

Although the measurement of cardiac troponin I (cTnI) and T (cTnT) has now become the cornerstone for diagnosing cardiac injury, both ischemic and non-ischemic, recent evidence has become available that many patients display extra-cardiac causes of cTn elevations and carry a considerably enhanced risk of future mortality. The current literature data suggests that cTn elevations may be equally common in patients with cardiac and extra-cardiac diseases. Among the latter cohort of patients, the leading extra-cardiac diseases which may be responsible for either cTnI or cTnT elevations include infectious diseases/sepsis, pulmonary disorders, renal failure, malignancy, as well as gastrointestinal…

030213 general clinical medicinemedicine.medical_specialtycardiac injuryClinical Biochemistry030209 endocrinology & metabolismSepsislcsh:Biochemistry03 medical and health sciences0302 clinical medicineTroponin complexInternal medicineTroponin IOpinion Papermedicinelcsh:QD415-436Myocardial infarctionStrokeCause of deathbiologybusiness.industrytroponinBiochemistry (medical)medicine.diseaseTroponinmortalitymyocardial infarctionHeart failurecardiac injury mortality myocardial infarction troponinCardiologybiology.proteincardiovascular systembusinessJournal of Medical Biochemistry
researchProduct